Clinical trial · Interventional
Geriatric and Oncologic Assessment Before Treatment
Significance of Geriatric Assessment for Optimal Treatment of Older Cancer Patients
NCT02671994CI-TRIAL-00036359GOATunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In a randomized controlled trial, the investigators wish to investigate, if oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in older frail patients with gynaecologic and urologic cancer is superior to standard assessment (PS and clinical assessment) in oncologic treatment decision.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| G8 screening | Other | — | UNRESOLVED |
| Geriatric assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- A (experimental group)
- description
- Oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in addition to standard assessment (ECOG Performance Status + clinical assessment).
- interventionNames
- Other: G8 screening
- Other: Geriatric assessment
- type
- NO_INTERVENTION
- label
- B (control group)
- description
- Oncologic treatment decision based on standard assessment (ECOG Performance Status + clinical assessment).
Primary outcomes (1)
- measure
- Feasibility of planned oncologic treatment (number of participants, who complete the planned oncologic treatment)
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically verified gynaecologic cancer (ovarian, uterine, or cervical cancer) or urologic cancer (prostate, bladder, or kidney cancer). * Suited for first line medical oncologic treatment with chemotherapy and/or targeted therapy. * Age ≥ 70 years. * Understands, speaks, and writes Danish. * Signed informed consent. Exclusion Criteria: * Previous cancer diagnosis except for carcinoma in situ of the cervix or skin cancer other than malignant melanoma. * Previous chemotherapy and/or targeted therapy for current cancer diagnosis. * Previous radiation therapy or concomitant radiotherapy for current cancer diagnosis. * Surgery within the last 4 weeks.
References
Publications (1)
- DERIVEDNadaraja S, Matzen LE, Jorgensen TL, Dysager L, Knudsen AO, Jeppesen SS, Moller S, Herrstedt J; Academy of Geriatric Cancer Research (AgeCare). The impact of comprehensive geriatric assessment for optimal treatment of older patients with cancer: A randomized parallel-group clinical trial. J Geriatr Oncol. 2020 Apr;11(3):488-495. doi: 10.1016/j.jgo.2019.06.019. Epub 2019 Jul 3. PMID 31279749